Last Build Date: Fri, 30 Sep 2016 18:06:00 -0400Copyright: Copyright 1995-2016 The Motley Fool. All rights reserved.
Fri, 30 Sep 2016 18:06:00 -0400Despite recent buyout rumors, the big bike maker is apparently staying public, but it may want to seriously consider the benefits of the alternative.
Fri, 30 Sep 2016 17:59:00 -0400These stocks helped lead the market higher. Find out why.
Fri, 30 Sep 2016 17:30:00 -0400While a Twitter acquisition could be a wise strategic move for many tech companies, investors have to wonder: Is there be a better use for that cash?
Fri, 30 Sep 2016 17:15:00 -0400The cost of solar energy may be falling faster than anyone expected.
Fri, 30 Sep 2016 17:07:00 -0400Why Costco and CalAmp stood out as indexes surged higher on Friday.
Fri, 30 Sep 2016 16:44:00 -0400Collaboration partner Roche Holdings is enrolling patients in a study of RG7916, a therapy for spinal muscular atrophy.
Fri, 30 Sep 2016 16:30:00 -0400The company provides two updates on the government's plans to buy its anthrax vaccines.
Fri, 30 Sep 2016 16:25:00 -0400Shares of the global bank are rising on reports that it may pay less to settle with the DOJ than originally feared.
Fri, 30 Sep 2016 16:05:00 -0400Coca-Cola enjoys a stock-market history as rich as its cultural legacy, though recent changes in consumer tastes will require the company to adjust its business to remain successful.
Fri, 30 Sep 2016 16:04:00 -0400The global refreshments powerhouse continued to benefit from revenue concentration in the U.S., raising EPS guidance alongside a positive fiscal third-quarter 2016 report.
Fri, 30 Sep 2016 15:57:00 -0400The government services provider tumbled after losing a key contract in Kuwait.
Fri, 30 Sep 2016 14:47:00 -0400The tech IPO scene is about to get a lot busier after taking a breather.
Fri, 30 Sep 2016 14:45:00 -0400Allergan, Bristol-Myers Squibb, and Pfizer may be worth buying right now. Here's why.
Fri, 30 Sep 2016 14:45:00 -0400Short-term macro headwinds are holding back the M2M specialist's overall growth.
Fri, 30 Sep 2016 14:20:00 -0400Looking for the next big thing? It could be one of these three companies.
Fri, 30 Sep 2016 14:11:00 -0400Why traditional energy play BP is piquing our interest this week and some points for investors to consider.
Fri, 30 Sep 2016 14:06:00 -0400Hakan Samuelsson's comments suggest that the automaker will employ a Level 4 system.
Fri, 30 Sep 2016 13:49:00 -0400The Mac maker should be focusing on growing the rest of the Americas.
Fri, 30 Sep 2016 13:40:00 -0400Citigroup's shares trade for a bigger discount to book value than any other blue chip bank stock.
Fri, 30 Sep 2016 13:40:00 -0400Fifty-five percent of Americans start their online product searches on Amazon.
Fri, 30 Sep 2016 13:11:00 -0400Lexmark is really close to getting bought out. Here's what investors need to know.
Fri, 30 Sep 2016 13:03:00 -0400These three growth stocks are cheap now, but they might not stay cheap for much longer.
Fri, 30 Sep 2016 12:40:00 -0400An internal investigation related to potentially improper payments and the resignation of its president have investors on edge.
Fri, 30 Sep 2016 12:29:00 -0400Shares fall in response to bad news from a competing drug's clinical trial.
Fri, 30 Sep 2016 12:23:00 -0400Could farming be a key addition to the solar industry?
Fri, 30 Sep 2016 12:23:00 -0400Rumors that some major tech names are interested in acquiring Twitter have sent the stock soaring, but some investors would rather see the company have a little more runway as a standalone business.
Fri, 30 Sep 2016 12:21:00 -0400Debt can put you on the fast track to financial insecurity, but there are times when debt can be necessary and helpful.
Fri, 30 Sep 2016 12:20:00 -0400The key hire adds to an impressive (and necessary) recruiting streak as the company prepares for vigorous growth.
Fri, 30 Sep 2016 12:03:00 -0400At first glance, Square has produced some big losses. But that's not the whole story.
Fri, 30 Sep 2016 12:01:00 -0400This dynamic duo appears to be on track to give Gilead's portfolio of hepatitis C products a run for its money.
Fri, 30 Sep 2016 11:38:41 -0400Now here's the real question: Should you buy Qualcomm stock?
Fri, 30 Sep 2016 11:31:00 -0400The cigarette giant isn't moving as aggressively as its partner on a key initiative.
Fri, 30 Sep 2016 11:20:00 -0400Cisco Systems, Bristol-Meyers-Squibb, and W.W. Grainger all look to be great investments over the next 10 years.
Fri, 30 Sep 2016 11:00:00 -0400What Smart Sand does and why it’s confident enough to go public in the oil industry in this climate.
Fri, 30 Sep 2016 10:48:00 -0400Settling a lawsuit with one of its major investors could be the best thing to happen to the solar energy company this year.
Fri, 30 Sep 2016 10:29:00 -0400In its bid to become even more like HBO, Netflix is even copying its content budget.
Fri, 30 Sep 2016 10:11:00 -0400Cisco's former "chief futurist" shares his thoughts about the future of connectivity.
Fri, 30 Sep 2016 09:45:00 -0400Progress was made in 2016, but next year will be even more important.
Fri, 30 Sep 2016 09:45:00 -0400These two stocks have a lot of positives to offer investors, but recent guidance weakness has contributed to a stock price beating. If the companies bounce back, these could be hidden dividend gems.
Fri, 30 Sep 2016 09:43:00 -0400Ligand Pharmaceuticals has returned over 1,160% since the beginning of 2011.
Fri, 30 Sep 2016 09:24:00 -0400These stocks give you monthly income, but they're not all great long-term investments.
Fri, 30 Sep 2016 09:22:00 -0400The e-commerce giant is expanding its grocery delivery service to even more cities. Can it take over yet another industry?
Fri, 30 Sep 2016 09:19:00 -0400The coffee chain is launching a line of ready-to-drink coffee beverages to be available in grocery and other stores.
Fri, 30 Sep 2016 09:11:00 -0400Jawbone's lack of inventory is anything but reassuring that the company is operating normally.
Fri, 30 Sep 2016 09:07:00 -0400Deutsche Bank downgrades the stock, making its recent downtrend even worse.
Fri, 30 Sep 2016 09:05:00 -0400The FDA's conditional approval of Exondys 51 to treat Duchenne muscular dystrophy came amid deep controversy, and fundamental questions about what the agency's priorities should be.
Fri, 30 Sep 2016 08:49:00 -0400Product competitiveness and cost structure directly affect the company's gross profit.
Fri, 30 Sep 2016 08:40:00 -0400Everybody and his dog knows the big blue chip dividend players, but there are plenty of other hidden gems out there waiting to be uncovered. Here are two solid dividend stocks you've probably never heard of.
Fri, 30 Sep 2016 08:25:00 -0400Big Blue has been on a nice roll of late, but there’s still room to grow if it’s able to deliver in a few key areas.
Fri, 30 Sep 2016 08:05:00 -0400These two beleaguered stocks have much in common. Which has the better odds of bouncing back?
Fri, 30 Sep 2016 07:47:00 -0400Each one has already posted big gains year-to-date, but I don't think their rallies are over yet.